Asklepios BioPharma Launches New Biotech Actus Therapeutics Post author:Sam Post published:December 14, 2017 Post category:BioPharma Asklepios BioPharma is forming a new biotech portfolio company, Actus Therapeutics. Source: BioSpace You Might Also Like Biogen's Victory Over $4 Billion MS Patent Spat Makes Company an Even More Attractive M&A Target March 21, 2017 FDA Green Lights Gilead's Vosevi, With a Black Box Warning Attached July 18, 2017 How Patrick Soon-Shiong's Generous Gift Violated State Laws October 19, 2017
Biogen's Victory Over $4 Billion MS Patent Spat Makes Company an Even More Attractive M&A Target March 21, 2017
